You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Unresectable NSCLC

Showing 1 - 25 of 5,982
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes

Recruiting
  • Unresectable /Inoperable Locally Advanced (Stage II-III) Non-small Cells Lung Cancer (NSCLC)
    • Grozny, Russian Federation
    • +4 more
    May 31, 2023

    Pathological Tumor and Lymph Node Responses After Neoadjuvant

    Completed
    • Non Small Cell Lung Cancer
    • +3 more
    • Timing of drug administration
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Nov 24, 2022

    NSCLC Trial in Tampa, Chapel Hill, Durham (Thoracic Radiotherapy, Platinum Based Chemotherapy, Ipilimumab)

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Thoracic Radiotherapy
    • +3 more
    • Tampa, Florida
    • +2 more
    Sep 30, 2022

    NSCLC Trial (Atezolizumab, Tiragolumab)

    Not yet recruiting
    • NSCLC
    • (no location specified)
    Apr 5, 2023

    NSCLC Trial in Changsha (Sugemalimab and Chemotherapy)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Sugemalimab and Chemotherapy
    • Changsha, China
      Hunan Cancer Hospital
    Jul 7, 2023

    Non Small Cell Lung Cancer, NSCLC, Lung Cancer Trial in Port Saint Lucie, Greenville (BL-B01D1)

    Recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • Port Saint Lucie, Florida
    • +1 more
    Aug 11, 2023

    Lung Cancer, Nonsmall Cell, Lung Cancer Stage III Trial (combination product, drug, procedure, radiation)

    Not yet recruiting
    • Lung Cancer, Nonsmall Cell
    • Lung Cancer Stage III
    • Nivolumab and Chemotherapy
    • +3 more
    • (no location specified)
    Aug 15, 2023

    NSCLC Trial in Cleveland (Durvalumab, Proton beam therapy RT)

    Active, not recruiting
    • Non-Small Cell Lung Cancer
    • Cleveland, Ohio
      University Hospitals Cleveland Medical Center, Case Comprehensiv
    Jul 5, 2022

    NSCLC, Stage III Trial in Beijing (Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC),

    Recruiting
    • NSCLC, Stage III
    • Beijing, Beijing, China
      Beijing Tsinghua Chang Gung Hospital
    Nov 4, 2022

    NSCLC Trial in Shanghai (Tislelizumab, Sitravatinib)

    Recruiting
    • Non-small Cell Lung Cancer
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Dec 15, 2021

    Omitting Clinical Target Volume in Radical Treatment of

    Not yet recruiting
    • Immunotherapy
    • +3 more
    • IMRT+adjuvant immunotherapy
    • (no location specified)
    Jun 9, 2023

    Stage III NSCLC, Locally Advanced, Unresectable Trial (standard Radiotherapy, Chemotherapy, Immunotherapy)

    Not yet recruiting
    • Stage III Non-small Cell Lung Cancer
    • +2 more
    • standard Radiotherapy
    • +3 more
    • (no location specified)
    Oct 20, 2023

    Locally Advanced NSCLC Trial in Beijing (Camrelizumab, PD-1 mAb, Apatinib, VEGFR2 antibody)

    Recruiting
    • Locally Advanced Non-Small Cell Lung Cancer
    • Camrelizumab, PD-1 monoclonal antibody
    • Apatinib, VEGFR2 antibody
    • Beijing, China
      National Cancer Center/Cancer Hospital, Chinese Academy of Medic
    Aug 15, 2022

    NSCLC Trial in Salvador, Belo Horizonte, São Paulo

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
      • Salvador, Bahia, Brazil
      • +3 more
      Nov 28, 2022

      China With Non-Small-Cell Lung Cancer That is Unable to be

      Not yet recruiting
      • Carcinoma, Non-Small-Cell Lung
        • (no location specified)
        May 16, 2023

        Lung Cancer, Stage III Lung Cancer, Unresectable Lung Carcinoma Trial in Barcelona (procedure, diagnostic test, drug)

        Recruiting
        • Lung Cancer
        • +2 more
        • Sample collection
        • +3 more
        • Barcelona, Spain
          Parc de Salut Mar - Hospital del Mar
        Dec 8, 2022

        NSCLC Stage III, KRAS P.G12C Trial in Spain (Sotorasib)

        Recruiting
        • Non-small Cell Lung Cancer Stage III
        • KRAS P.G12C
        • Badalona, Barcelona, Spain
        • +19 more
        Jul 6, 2022

        Unresectable NSCLC (NSCLC) and Urothelial Cancer Trial in India (Durvalumab)

        Recruiting
        • Unresectable Non-small Cell Lung Cancer (NSCLC) and Urothelial Cancer
        • Bangalore, India
        • +10 more
        Aug 24, 2022

        Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance

        Not yet recruiting
        • Carcinoma, Non-Small-Cell Lung
          • (no location specified)
          Apr 21, 2023

          NSCLC, Stage III Trial in Chengdu (GFH018, Toripalimab, Paclitaxel)

          Not yet recruiting
          • NSCLC, Stage III
          • Chengdu, Sichuan, China
            West China Hospital, Sichuan University
          May 23, 2022

          NSCLC (NSCLC) Trial in Jinan (WX-0593 Tablets, chemo, Thoracic Radiation Therapy(TRT))

          Recruiting
          • Non-small Cell Lung Cancer (NSCLC)
          • WX-0593 Tablets
          • +2 more
          • Jinan, Shandong, China
            Shandong Cancer Hospital and Institute
          Apr 24, 2022

          Unresectable Lung Non-Small Cell Carcinoma Trial (serplulimab plus chemo as conversion treatment)

          Not yet recruiting
          • Unresectable Lung Non-Small Cell Carcinoma
          • serplulimab plus chemotherapy as conversion treatment
          • (no location specified)
          Apr 27, 2023

          Non Small Cell Lung Cancer Trial in Nashville (AMG 510, MVASI)

          Recruiting
          • Non Small Cell Lung Cancer
          • Nashville, Tennessee
            Vanderbilt Ingram Cancer Center
          Jun 28, 2022

          Breast Cancer Metastatic, Pancreatic Cancer, NSCLC, Metastatic Trial in Denver, Grand Rapids (ST316)

          Not yet recruiting
          • Breast Cancer Metastatic
          • +7 more
          • Denver, Colorado
          • +1 more
          Apr 28, 2023

          A Multi-center, Non-interventional, Prospective Study of

          Recruiting
          • NSCLC, Non-small-cell Lung Carcinoma
            • Arkhangelsk, Russian Federation
            • +14 more
            Aug 9, 2022